First‐in‐human high‐cumulative‐dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline

Previous phase I studies demonstrated safety and some beneficial effects of mesenchymal stem cells (MSCs) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). The aim of our study was to evaluate the safety, tolerability, and efficacy of a high cumulative dose of bone marrow MSCs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Averyanov, Alexander, Koroleva, Irina, Konoplyannikov, Mikhail, Revkova, Veronika, Lesnyak, Victor, Kalsin, Vladimir, Danilevskaya, Olesya, Nikitin, Alexey, Sotnikova, Anna, Kotova, Svetlana, Baklaushev, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Human Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954714/
https://www.ncbi.nlm.nih.gov/pubmed/31613055
http://dx.doi.org/10.1002/sctm.19-0037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954714/
https://www.ncbi.nlm.nih.gov/pubmed/31613055
http://dx.doi.org/10.1002/sctm.19-0037

Ejemplares similares